Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.99
-0.42 (-6.55%)
At close: Aug 13, 2026, 4:00 PM EDT
6.07
+0.08 (1.34%)
After-hours: Aug 13, 2026, 7:34 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.95 billion as of August 13, 2026. Its market cap has increased by 145.86% in one year.
Market Cap
1.95B
Enterprise Value
1.55B
1-Year Change
145.86%
Ranking
Category
Stock Price
$5.99
ChartMarket Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.95B, an increase of 182.69%. That is a compound annual growth rate of 19.30%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 13, 2026 | 1.96B | 29.77% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Palvella Therapeutics | 2.24B |
| Septerna | 2.23B |
| ADMA Biologics | 2.22B |
| Mesoblast | 2.21B |
| Biohaven | 2.19B |
| Vera Therapeutics | 2.18B |
| SELLAS Life Sciences Group | 2.16B |
| Ocular Therapeutix | 2.14B |